Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide’s effect on glycemia

Essentiality of Portal Vein Receptors in Hypoglycemic Counterregulation: Direct Proof Via Denervation in Male Canines

(2014) Viorica Ionut et al.   ENDOCRINOLOGY

Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

(2012) Daniel J. Cuthbertson et al.   PLoS One

The role of the autonomic nervous liver innervation in the control of energy metabolism

(2010) Chun-Xia Yi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Unraveling the Science of Incretin Biology

(2009) Michael A. Nauck   European Journal of Internal Medicine

Exenatide can reduce glucose independent of islet hormones or gastric emptying

(2008) Viorica Ionut et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver

(2008) D. Zheng et al.   DIABETES